https://www.selleckchem.com/pr....oducts/bezafibrate.h
01). Moreover at T1 we found a significant increase in systolic and diastolic blood pressure (P ≤ .001) and 24-hour proteinuria (P less then .001) compared to baseline, whereas no changes in IMT and ABI were detected. CONCLUSION The changes observed overtime after sunitinib treatment in terms of markers of early endothelial dysfunction, blood pressure, as well as in glucose/insulin metabolism and proteinuria may contribute to increase CV risk in RCC patients and suggest a strict follow-up in this setting. Larger evidences are mandat
Like
Comment
Share
